Annual Statements Open main menu
  1. Annual Statements
  2. » Companies
  3. » Bruker Cellular Analysis, Inc.
  4. » Quarter Report: 2021 March (Form 10-Q)

Bruker Cellular Analysis, Inc. - Quarter Report: 2021 March (Form 10-Q)


Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark one)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021

or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from___ to___
Commission file number: 001-39388
bli-20210331_g1.jpg
Berkeley Lights, Inc.
(Exact name of registrant as specified in its charter)
Delaware35-2415390
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
5858 Horton Street, Suite 320
Emeryville, California 94608
(Address of principal executive offices, including zip code)
(510) 858-2855
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, $0.00005 par valueBLIThe Nasdaq Global Select Market


Table of Contents
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒
Smaller reporting company☐Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of April 30, 2021, 66,724,383 shares of the registrant’s common stock, $0.00005 par value per share, were outstanding.


Table of Contents
BERKELEY LIGHTS, INC.
FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021
Table of Contents
Page(s)
Item 1.
Item 3.
Item 4.


Table of Contents
PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements (Unaudited).
Berkeley Lights, Inc.
Condensed Consolidated Balance Sheets
March 31,
2021		December 31,
2020
(In thousands, except share and per share data)(unaudited)
Assets
Current assets:
Cash and cash equivalents$230,165 $233,408 
Trade accounts receivable16,432 12,939 
Inventory10,941 11,047 
Prepaid expenses and other current assets8,240 8,175 
Total current assets265,778 265,569 
Restricted cash270 270 
Property and equipment, net17,152 14,544 
Operating lease right-of-use assets16,223 16,718 
Other assets3,528 2,557 
Total assets$302,951 $299,658 
Liabilities and Stockholders’ Equity
Current liabilities:
Trade accounts payable$6,934 $3,491 
Accrued expenses and other current liabilities8,153 8,401 
Current portion of notes payable16,592 11,594 
Deferred revenue7,929 5,482 
Total current liabilities39,608 28,968 
Notes payable, net of current portion3,320 8,301 
Deferred revenue, net of current portion2,301 1,709 
Lease liability, long-term15,356 15,899 
Total liabilities60,585 54,877 
Commitments and contingencies (Note 13)
Stockholders’ equity:
Convertible preferred stock, $0.00005 par value. Authorized 10,000,000 shares at March 31, 2021 and December 31, 2020, respectively; no shares issued and outstanding at March 31, 2021 and December 31, 2020
— — 
Common stock, $0.00005 par value. Authorized 300,000,000 shares at March 31, 2021 and December 31, 2020; issued and outstanding 66,384,736 and 64,486,246 shares at March 31, 2021 and December 31, 2020, respectively
4 3 
Additional paid-in capital449,681 436,662 
Accumulated deficit(207,319)(191,884)
Total stockholders’ equity242,366 244,781 
Total liabilities and stockholders’ equity$302,951 $299,658 
See accompanying notes to these condensed consolidated financial statements.
1

Table of Contents
Berkeley Lights, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

Three months ended March 31,
20212020
(In thousands, except share and per share data)
Revenue:
Product revenue$13,533 $10,683 
Service revenue5,095 3,095 
Total revenue18,628 13,778 
Cost of sales:
Product cost of sales3,703 2,620 
Service cost of sales2,474 1,179 
Total cost of sales6,177 3,799 
Gross profit12,451 9,979 
Operating expenses:
Research and development13,027 10,976 
General and administrative8,967 3,997 
Sales and marketing5,606 3,234 
Total operating expenses27,600 18,207 
Loss from operations(15,149)(8,228)
Other income (expense):
Interest expense(354)(357)
Interest income66 151 
Other income (expense), net19 25 
Loss before income taxes(15,418)(8,409)
Provision for income taxes17 16 
Net loss and net comprehensive loss$(15,435)$(8,425)
Net loss attributable to common stockholders per share, basic and diluted$(0.24)$(3.02)
Weighted-average shares used in calculating net loss per share, basic and diluted65,259,398 3,047,967 

See accompanying notes to these condensed consolidated financial statements.
2

Table of Contents
Berkeley Lights, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited)


Three Months Ended March 31, 2021
Convertible
Preferred Stock		Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Stockholders'
Equity
(In thousands, except per share data)SharesAmountSharesAmount
Balances at December 31, 2020— $— 64,486,246 $3 $436,662 $(191,884)$244,781 
Shares issued in connection with:
Exercise of stock options— — 1,778,130 1 6,361 — 6,362 
Vesting of restricted stock units— — 5,000 — — — — 
Employee stock purchase plan— — 115,360 — 2,157 — 2,157 
Stock-based compensation— — — — 4,501 — 4,501 
Net loss— — — — — (15,435)(15,435)
Balances at March 31, 2021— $— 66,384,736 $4 $449,681 $(207,319)$242,366 
Three Months Ended March 31, 2020
Convertible
Preferred Stock		Common StockAdditional
Paid-in
Capital		Accumulated
Deficit		Total
Stockholders'
Equity
(In thousands, except per share data)SharesAmountSharesAmount
Balances at December 31, 201950,462,272 $224,769 3,073,067 $— $9,314 $(150,300)$83,783 
Shares issued in connection with:
Exercise of stock options— — 8,580 — 21 — 21 
Vesting of shares subject to repurchase from early exercised options— — — — 88 — 88 
Stock-based compensation— — — — 1,213 — 1,213 
Net loss— — — — — (8,425)(8,425)
Balances at March 31, 202050,462,272 $224,769 3,081,647 $— $10,636 $(158,725)$76,680 

See accompanying notes to these condensed consolidated financial statement
3

Table of Contents
Berkeley Lights, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)

Three months ended March 31,
(In thousands)20212020
Cash flows from operating activities:
Net loss$(15,435)$(8,425)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation1,345 1,319 
Stock-based compensation4,494 1,179 
Amortization of operating lease right-of-use assets495 468 
Non-cash interest and other (income) expense related to debt and note receivable agreements18 17 
Provision for excess and obsolete inventory44 6 
Loss on disposal and impairment of property and equipment13 13 
Changes in operating assets and liabilities:
Trade accounts receivable(3,493)(687)
Inventory(2,744)(3,469)
Prepaid expenses, other current assets and other assets(1,036)613 
Trade accounts payable2,690 1,160 
Deferred revenue3,039 (2,026)
Accrued expenses and other current liabilities(429)336 
Operating lease liabilities(361)(492)
Net cash used in operating activities(11,360)(9,988)
Cash flows from investing activities:
Purchase of property and equipment(402)(760)
Net cash used in investing activities(402)(760)
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options6,362 21 
Proceeds from issuance of common stock under employee stock purchase plan2,157 — 
Net cash provided by financing activities8,519 21 
Net decrease in cash and cash equivalents and restricted cash(3,243)(10,727)
Cash and cash equivalents and restricted cash at beginning of period233,678 81,303 
Cash and cash equivalents and restricted cash at end of period$230,435 $70,576 

See accompanying notes to these condensed consolidated financial statements.
4
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)

(1)The Company and Basis of Presentation
Description of Business
Berkeley Lights, Inc. (the “Company” or “Berkeley Lights”) is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. Berkeley Lights’ platform is a fully integrated, end-to-end solution, comprised of proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems and advanced application and workflow software.
In 2017, Berkeley Lights incorporated BLI Europe International, Ltd. as a wholly-owned subsidiary in the United Kingdom to support Berkeley Lights’ planned expansion in Europe. In the third quarter of 2020, Berkeley Lights established a wholly owned foreign operating entity in China to further expand its operations. Berkeley Lights and its consolidated subsidiaries are hereinafter referred to as the “Company”. The Company’s headquarters are in Emeryville, California.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Berkeley Lights in this Quarterly Report have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation of S-X of the U.S. Securities and Exchange Commission (“the SEC”). Accordingly, these interim financial statements do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of Berkeley Lights’ management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial information have been included.
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in its condensed consolidated financial statements and the accompanying notes. Despite the Company’s intentions to establish accurate estimates and reasonable assumptions, actual results could differ materially from such estimates and assumptions. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or for any other period. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2020 included in the Annual Report on Form 10-K filed with the SEC on March 12, 2021.
Liquidity
The Company has experienced losses from its operations since its inception and has relied primarily on equity and debt financing to fund its operations to date. For the three months ended March 31, 2021, the Company had a consolidated net loss of $15.4 million and as of March 31, 2021 had an accumulated deficit of $207.3 million and unrestricted cash and cash equivalents of $230.2 million. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash and cash equivalents balance as of March 31, 2021 provides sufficient capital resources to continue its operations for at least 12 months from the issuance date of the accompanying consolidated financial statements.
Initial Public Offering
5
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The Company’s registration statement on Form S-1 related to its initial public offering (“IPO”) was declared effective on July 16, 2020 by the SEC, and the Company’s common stock began trading on the Nasdaq Global Select Market on July 17, 2020. On July 21, 2020, the Company closed its IPO, in which the Company sold 9,315,000 shares of common stock (which included 1,215,000 shares that were sold pursuant to the full exercise of the IPO underwriters’ option to purchase additional shares) at a price to the public of $22.00 per share. Including the option exercise, the Company received aggregate net proceeds of $187.9 million after deducting offering costs, underwriting discounts and commissions of $17.0 million.
Immediately prior to the completion of the IPO, 50,462,272 shares of convertible preferred stock then outstanding converted into an equivalent number of shares of common stock.
(2)Summary of Significant Accounting Policies
Significant accounting policies
The Company’s significant accounting policies are disclosed in its Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission and have not materially changed during the three months ended March 31, 2021.
Revenue Recognition
The Company derives revenue from two primary sources, primarily product and service revenues. Product revenues are comprised primarily of direct platform sales and product consumables revenues. Service revenues are comprised of revenue from joint development agreements, service and warranty, platform support and feasibility studies on the Company’s platforms. Revenues are recognized net of applicable taxes imposed on the related transaction.
The Company recognizes revenue when the Company satisfies the performance obligations under the terms of a contract and control of its products and services is transferred to its customers in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract based on stand-alone selling price, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.
The Company’s agreements with customers often include multiple performance obligations, which can sometimes be included in separate contracts entered into within a reasonably short period of time. The Company considers an entire customer arrangement to determine if separate contracts should be considered combined for the purposes of revenue recognition.
In order to determine the stand-alone selling price, the Company conducts a periodic analysis to determine whether various goods or services have an observable stand-alone selling price as well as to identify significant changes to current stand-alone selling prices. If the Company does not have an observable stand-alone selling price for a particular good or service, then the stand-alone selling price for that particular good or service is estimated using an approach that maximizes the use of observable inputs. The Company’s process for determining stand-alone selling price requires judgment and considers multiple factors that are reasonably available and maximizes the use of observable inputs that may vary over time depending upon the unique facts and circumstances related to each performance obligation. The Company believes that this method results in an
6
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
estimate that represents the price the Company would charge for the product offerings if they were sold separately.
For most of its performance obligations, the Company has established stand-alone selling price as a range rather than a single value, such range being plus or minus 15% of the weighted average of observable prices. If the contractually stated prices of all the performance obligations in a contract fall within their respective stand-alone selling price ranges, the Company will allocate the transaction price at the contractually stated amounts. In situations where the contractually stated price for one or more performance obligations in a contract fall(s) outside of their respective stand-alone selling price range, the Company will use the mid-point of the respective stand-alone selling price range for performance obligations in the contract priced outside of their respective stand-alone selling price range(s) and the contract values for performance obligations priced within their respective stand-alone selling price range(s), to allocate the transaction price on a relative stand-alone selling price basis.
Taxes, such as sales, value-add and other taxes, collected from customers concurrent with revenue generating activities and remitted to governmental authorities are not included in revenue. Shipping and handling costs associated with outbound freight are accounted for as a fulfillment cost and are included in cost of sales.
The following describes the nature of the Company’s primary types of revenue and the revenue recognition policies and significant payment terms as they pertain to the types of transactions the Company enters into with its customers.
Product revenues
Product revenues are comprised of two major revenue streams, direct platform sales and consumables. Direct platform sales revenues are comprised of advanced automation systems (including fully-paid workflow licenses) as well as Culture Station instruments. Direct platform sales also include revenue from subscription arrangements in which customers are able to subscribe to a specific workflow and pay a quarterly fee over a fixed period of time which covers the annual workflow license, the advanced automation system, as well as warranty and service. Consumables revenues are comprised of OptoSelect chips required to run the system as well as reagent kits. The Company’s standard arrangement with its customers is generally a purchase order or an executed contract. Revenue on product sales is recognized when control has transferred to the customer which typically occurs when the product has been shipped to the customer, risk of loss has transferred to the customer and the Company has a present right to payment for the system, chip or kit, as applicable. In certain limited circumstances when a product sale includes client acceptance provisions, the Company will first assess such terms to determine if the control of the good is being transferred to the customer in accordance with the agreed-upon specifications in the contract. To the extent that such acceptance provisions can be objectively determined to be aligned with the standard specifications of the arrangement, are defined and easily evaluated for completion, as well as do not afford the customer any additional rights or create additional performance obligations for the Company, such provisions would be determined perfunctory and would not preclude revenue recognition presuming all other criteria are met. If such acceptance provisions are considered to be substantive, revenue is recognized either when client acceptance has been obtained, client acceptance provisions have lapsed, or the Company has objective evidence that the criteria specified in the client acceptance provisions have been satisfied. Payment terms are generally thirty to ninety days from the date of invoicing.
On a limited basis, the Company also enters into fixed-term sales-type lease arrangements with certain qualified customers. Revenue from sales-type lease arrangements is generally recognized in a manner consistent with platform systems, assuming all other revenue recognition criteria have been met.


7
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Service revenues
Service revenues primarily consist of joint development agreements, service and warranty, training and installation services, platform support and feasibility studies on the Company’s advanced automation systems and workflows. The Company’s services are provided primarily on a fixed fee basis; from time to time these fixed fee contracts may be invoiced at the outset of the arrangements. The Company recognizes revenue from the sale of extended warranty and enhanced service warranty arrangements over the respective period, while revenue on feasibility studies is recognized over time, using an input measure of progress based on costs incurred to date relative to total expected costs. Revenue on platform support is recognized as the services are performed. Service contracts are typically short-term in nature. Payment terms are generally thirty to ninety days from the date of invoicing.
Joint development agreements are agreements whereby the Company provides services for the development of customized advanced automation systems, workflows or for customized workflows and consumables to meet a specific customer’s needs. Such contracts can be executed on a time-and-materials basis as well as include defined milestones associated with these development activities over extended periods of time, some in excess of twenty-four months. Typically, there are formal customer acceptance clauses as each milestone is completed, and an approval to proceed with the next milestone is generally required. The Company recognizes revenue over time, using an input measure of progress based on costs incurred to date relative to total expected costs. Payment terms are generally thirty to ninety days from the achievement of each milestone.
The Company places a constraint on a variable consideration estimate that focuses on possible future downward revenue adjustments (i.e., revenue reversals) if there is uncertainty that could prevent a faithful depiction of the consideration to which the Company expects to be entitled to. The constraint estimate is reassessed at each reporting date until the uncertainty is resolved.
Contract assets and contract liabilities
Contract assets include amounts where revenue recognized exceeds the amount invoiced to the customer and the right to payment is not solely subject to the passage of time. The Company’s contract asset balances of $3.8 million and $2.7 million as of March 31, 2021 and December 31, 2020, respectively, are primarily from its sales-type lease arrangements as well as its development and feasibility study agreements. The Company does not have impairment losses associated with contracts with customers for the three months ended March 31, 2021 and 2020.
Contract liabilities consist of fees invoiced or paid by the Company’s customers for which the associated services have not been performed and revenues have not been recognized based on the Company’s revenue recognition criteria described above. Such amounts are reported as deferred revenue on the condensed consolidated balance sheets. Deferred revenue that is expected to be recognized during the following twelve months is recorded as a current liability and the remaining portion is recorded as non-current.
Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term on the condensed consolidated balance sheet based on the timing of when the Company expects to complete the related performance obligations and invoice the customers. Contract liabilities are classified as current or long-term on the condensed consolidated balance sheet based on the timing when the revenue recognition associated with the related customer payments and invoicing is expected to occur.
Costs to obtain or fulfill a contract
Origination costs relate primarily to the payment of incentive bonuses that are directly related to sales transactions. Fulfillment costs generally include the direct cost of services such as platform support and feasibility studies.
8
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Origination and fulfillment costs that are internal to the Company are generally expensed when incurred because most of those costs are incurred concurrently with the delivery of the related goods and services, which are predominantly recognized at a point in time or are short-term in nature. The origination costs that are related to long-term development agreements are capitalized and amortized over the relevant service period.
The origination costs that are related to long-term development agreements are not material as of March 31, 2021 and 2020.
Stock-Based Compensation
The Company maintains an incentive compensation plan under which incentive stock options, nonqualified stock options and restricted stock units (“RSUs”) are granted primarily to employees and non-employee consultants. Stock-based compensation expense for stock-based awards is based on the grant date fair value. The Company determines the fair value of RSUs based on the closing value of its stock price listed on Nasdaq at the date of the grant.
The Company estimates the fair value of stock option awards on the grant date using the Black-Scholes option-pricing model. The fair value of stock option awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock option awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period, provided the grantee remains an employee or consultant of the Company through each applicable vesting date. The Company records a cumulative adjustment to compensation expense for performance-based awards if there is a change in determination of whether it is probable that the performance condition will be achieved. If the performance goals are not achieved, no compensation expense is recognized and any previously recognized compensation expense is reversed. The Company records forfeitures as they occur.
Product Warranties
The Company provides a 13-month assurance-type warranty on its platforms and chip consumables. Upon shipment, the Company establishes an accrual for estimated warranty expenses based on historical data and trends of product reliability and costs of repairing and replacing defective products. The Company exercises judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, estimated repair costs, freight, material, labor, and overhead costs. While management believes that historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues or component failure rates could result in future costs in excess of such estimates, or alternatively, improved quality and reliability in the Company’s products could result in actual expenses that are below those currently estimated.
Leases
The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter, if modified. The lease term includes any renewal options and termination options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment.
Lease expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.
9
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
For all leases, rent payments that are based on a fixed index or rate at the lease commencement date are included in the measurement of lease assets and lease liabilities at the lease commencement date.
The Company has elected the practical expedient to not separate lease and non-lease components. The Company’s non-lease components are primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.
The Company also acts as a lessor to provide equipment financing through sales-type lease arrangements with certain qualified customers. Revenue from sales-type leases is presented on a gross basis when the company enters into a lease to realize value from a product that it would otherwise sell in its ordinary course of business. Amounts due and receivable under these arrangements are recorded at the outset of the arrangement as a contract asset in prepaid expenses and other current assets and other assets until such time that invoices are issued in accordance with the terms of the lease, at which point they are recorded as trade accounts receivable in the condensed consolidated balance sheets.
Net Loss Attributable to Common Stockholders Per Share
Net loss attributable to common stockholders per share is computed by dividing the weighted-average number of common shares outstanding for the period. Diluted net loss per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive. In computing diluted net loss per share, the Company utilizes the treasury stock method.
The Company applies the two-class method to compute basic and diluted net loss or income per share when it has issued shares that meet the definition of participating securities. The two-class method determines net (loss) or income per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires net (loss) income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all net (loss) income for the period had been distributed. The Company’s convertible preferred stock participates in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.
Recently Issued and Adopted Accounting Standards
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to the accounting for income taxes. The Company adopted ASU 2019-12 effective January 1, 2021; such adoption did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures.
(3)Significant Risks and Uncertainties Including Business and Credit Concentrations
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and trade receivables. The Company’s cash and cash equivalents are held by large, credit worthy financial institutions. The Company invests its excess cash in money market funds. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in these banks may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents.
The Company controls credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based
10
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
on management’s assessment of the collectability of specific customer accounts and the aging of the related invoices and represents the Company’s best estimate of probable credit losses in its existing trade accounts receivable. At each of March 31, 2021 and 2020, the Company had not recorded any material allowance for doubtful accounts.
Most of the Company’s customers are located in the United States and Asia Pacific. For the three months ended March 31, 2021, two customers accounted for 11% and 10% of revenue. For the three months ended March 31, 2020, six customers accounted for 17%, 14%, 13%, 13%, 12% and 12% of revenue.
As of March 31, 2021, five customers comprised 25%, 22%, 12%, 11% and 11% of accounts receivable. As of December 31, 2020, three customers accounted for 42%, 21% and 15% of accounts receivable.
(4)Revenue From Contracts With Customers
Disaggregation of revenue
The following table depicts the disaggregation of revenue by type of customer or sales channel, market segment as defined by nature of workflows and activities of the end customer and timing of revenue recognition (in thousands):
Three months ended March 31,
20212020
Type of Sales Channel
Direct sales channel$10,439 $11,981 
Distributor channel8,189 1,797 
Net revenues$18,628 $13,778 
Market
Antibody therapeutics$15,114 $11,821 
Synthetic biology1,984 1,606 
Gene therapy1,225 — 
Cell therapy305 351 
Net revenues$18,628 $13,778 
Timing of Revenue Recognition
Goods and services transferred at a point in time$13,064 $10,688 
Goods and services transferred over time5,564 3,090 
Net revenues$18,628 $13,778 
Revenues by market are determined by the revenue associated with workflows that the Company’s customers are utilizing, primarily on our Beacon platform, or by the nature of the workflows that the Company is developing under joint development and partnership agreements. Revenues by geographical markets are presented in Note 15 to these condensed consolidated financial statements.
Performance Obligations
11
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
A significant number of the Company’s product and service sales, as well as its feasibility study arrangements, are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less.
As of March 31, 2021, the aggregate amount of remaining performance obligations that are unsatisfied or partially unsatisfied related to customer contracts was $6.4 million, which includes deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately 37% is expected to be recognized to revenue in the next 12 months, with the remainder recognized afterwards.
Contract balances
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands):
March 31,
2021		December 31,
2020
Trade accounts receivable$16,432 $12,939 
Contract assets, which are included in “Prepaid expenses and other current assets”1,407 1,310 
Contract assets, long-term, which are included in “Other assets”2,403 1,375 
Deferred revenue (current)7,929 5,482 
Deferred revenue (non-current)2,301 1,709 
The contract liabilities of $10.2 million and $7.2 million as of March 31, 2021 and December 31, 2020, respectively, consisted of deferred revenue related to extended warranty service agreements and advanced billings on advanced automation systems arrangements. Revenue recorded during the three months ended March 31, 2021 included $2.5 million of previously deferred revenue that was included in contract liabilities as of December 31, 2020.
Sales-type lease arrangements
The Company also enters into sales-type lease arrangements with certain qualified customers. Revenue related to lease elements from sales-type leases is presented as product revenue and was $1.7 million and none for the three months ended March 31, 2021 and 2020, respectively.
The following tables presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of March 31, 2021 (in thousands):
Year ending December 31,Sales-Type
Leases
Remainder of 2021$1,328 
20222,098 
2023445 
2024 and thereafter853 
Total undiscounted cash flows$4,724 
Less: unearned income741 
Total amounts due from customers, gross$3,983 
(5)Balance Sheet Accounts
12
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Inventory
The following table shows the components of inventory (in thousands):
March 31,
2021		December 31,
2020
Raw materials$6,184 $6,675 
Finished goods4,757 4,372 
Total$10,941 $11,047 
Prepaid expenses and other current assets
The following table shows the components of prepaid expenses and other current assets (in thousands):
March 31,
2021		December 31,
2020
Contract asset$1,407 $1,310 
Vendor deposits1,363 1,346 
Deferred costs357 292 
Prepaid insurance1,427 2,401 
Other3,686 2,826 
Total$8,240 $8,175 
Accrued expenses and other current liabilities
The following table shows the components of accrued expenses and other current liabilities (in thousands):
March 31,
2021		December 31,
2020
Accrued payroll and employee related expenses$3,419 $4,152 
Lease liability – short-term2,090 1,909 
Accrued product warranty1,268 1,271 
Accrued legal expenses896 606 
Other480 463 
Total$8,153 $8,401 
(6)Fair Value of Financial Instruments
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.
The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate fair value due to their relatively short maturities. The Company classifies its cash equivalents, which are comprised primarily of money market funds, within Level 1, as it uses quoted market prices in the determination of fair value.
13
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands):
March 31,
2021		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Assets
Cash equivalents$25,134 $25,134 $— $— 
Total$25,134 $25,134 $— $— 

December 31,
2020		Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable
Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)
Assets
Cash equivalents$25,133 $25,133 $— $— 
Total$25,133 $25,133 $— $— 
The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands):
March 31, 2021December 31, 2020
Carrying
Value		Fair ValueCarrying
Value		Fair Value
Long-term debt, including current maturities$19,912 $19,592 $19,895 $19,949 
The Company estimated the fair value of its long-term debt using a market-based approach that considers an average cost of debt. The Company has incorporated its own credit risk for all liability fair value measurements. Such fair value measurements are considered Level 2 under the fair value hierarchy.
The Company did not have any transfers of financial assets measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3 for any of the periods presented.
14
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(7)Property and Equipment, net
Property and equipment, net comprised the following (in thousands):
March 31,
2021		December 31,
2020
Equipment, tooling and molds$24,295 $21,118 
Computer software and equipment2,301 2,153 
Furniture, fixtures and other1,751 1,739 
Leasehold improvements5,603 5,597 
Construction in process874 275 
Total property and equipment$34,824 $30,882 
Less: Accumulated depreciation(17,672)(16,338)
Property and equipment, net$17,152 $14,544 
Total depreciation expense for the three months ended March 31, 2021 and 2020 was $1.3 million and $1.3 million, respectively.
During the three months ended March 31, 2021 and 2020, losses on the impairment and disposal of property and equipment was not material.
(8)Leases
The Company leases office, manufacturing, distribution and laboratory facilities in Emeryville, California under multiple operating leases totaling approximately 77,844 square feet. All of the leases expire on March 31, 2028.
In addition, the Company also leases multiple facilities in Shanghai, China under operating leases that expire at various dates, including additional office and laboratory facilities under an operating lease agreement that was entered into in July 2020. These leases expire at various dates, the latest of which is August 2023.
Certain of the Emeryville leases contain options to early terminate the lease and options to extend the lease for an additional term. However, the Company is not reasonably certain to exercise any of these options. The monthly base rental rate of the leases is subject to adjustment upon renewal based on then current market rental conditions.
Future payments associated with the Company’s operating lease liabilities as of March 31, 2021 is as follows (in thousands):
15
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Operating leases
Undiscounted lease payments for the year ending December 31,
Remainder of 2021$2,490 
20223,258 
20233,284 
20243,338 
20253,439 
Thereafter8,127 
Total undiscounted lease payments23,936 
Less: implied interest(5,073)
Less: tenant improvement allowances receivable(1,417)
Present value of operating lease payments17,446 
Less: current portion(2,090)
Total long-term operating lease liabilities$15,356 
Rent expense for the three months ended March 31, 2021 and 2020 was $0.8 million and $0.6 million, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for operating leases were $0.5 million and $0.3 million for the three months ended March 31, 2021 and 2020, respectively, including non-lease components such as common area maintenance fees.
The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):
Three months ended March 31, 2021
Cash paid for amounts included in the measurement of lease liabilities$691 
The following summarizes additional information related to operating leases:
March 31, 2021
Weighted-average remaining lease term (years)6.93
Weighted-average discount rate7.03 %

The Company also enters into leasing transactions in which the Company is the lessor, which to date have been classified as sales-type leases. See Note 4 of these condensed consolidated financial statements for the related lease disclosures.
(9)Notes Payable
In May 2018, the Company entered into a Loan and Security Agreement with East West Bank (the “EWB Loan Agreement”) providing it the ability to borrow up to $20.0 million.
The EWB Loan Agreement has a term of 48 months and carries an interest only period through May 2021, such interest only period subject to extension based on certain cash and revenue metrics. In March 2020, the EWB Loan Agreement was amended to extend the interest only period by an additional twelve months through May 2021. There were no other changes to the loan agreement associated with this amendment. The note payable is
16
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
collateralized by substantially all the assets of the Company, excluding intellectual property, which is subject to a negative pledge. The note carries an interest at a fixed rate of 6.73% per annum.
The following is a schedule of payments due on notes payable as of March 31, 2021 (in thousands):
March 31,
2021
Year Ending December 31:
Remainder of 2021$12,495 
20228,475 
Total payments due20,970 
Less:
Interest payments, loan discounts and financing costs(1,058)
Current portion, less loan discounts and financing costs(16,592)
Notes payable, net of current portion$3,320 
Total interest cost incurred for the three months ended March 31, 2021 and 2020 was $0.4 million and $0.4 million, respectively.
(10)Stock Compensation Plans
2011 Equity Incentive Plan
As of March 31, 2021, the number of shares of common stock issuable under the 2011 Equity Incentive Plan, as amended (the “2011 Plan”), was 6,938,283 shares, including shares issuable upon the exercise of outstanding awards. Following the adoption of the 2020 Incentive Award Plan in July 2020, any awards outstanding under the 2011 Plan continue to be governed by their existing terms but no further awards may be granted under the 2011 Plan.
2020 Incentive Award Plan
In July 2020, the Company’s Board of Directors approved the 2020 Incentive Award Plan (the “2020 Plan”). The initial number of shares authorized and available for issuance in connection with the grant of future awards is 6,750,000. As of March 31, 2021, the number of shares remaining for issuance under the 2020 Plan was 7,577,297, which includes awards granted and outstanding under the 2011 Plan that have been forfeited or lapsed unexercised after the effective date of the 2020 Plan.
2020 Employee Stock Purchase Plan
In July 2020, the Company’s Board of Directors approved the 2020 Employee Stock Purchase Plan (the “ESPP”). A total of 612,150 shares of common stock was initially reserved for issuance under the ESPP. The price at which common stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. During the three months ended March 31, 2021, 115,360 shares of common stock were issued under the ESPP. As of March 31, 2021, there were 1,142,002 shares available for issuance in connection with the current and future offering periods under the ESPP.
Stock-based compensation
Stock-based compensation related to the Company's stock-based awards was recorded as an expense and allocated as follows (in thousands):
17
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Three months ended March 31,
20212020
Cost of sales$42 $6 
Research and development1,061 511 
General and administrative1,372 529 
Sales and marketing2,019 133 
Total stock-based compensation$4,494 $1,179 
Stock-based compensation capitalized in inventory was not material as of March 31, 2021 and December 31, 2020.
(11)Income Taxes
The Company’s provision for income taxes was $17,000 and $16,000, respectively, for the three months ended March 31, 2021 and 2020. The Company maintains a full valuation allowance on its deferred tax assets, and intends to do so until there is sufficient evidence to support the reversal of all or some portion of these allowances.
(12)Statements of Cash Flows
The supplemental cash flow information consists of the following (in thousands):
Three months ended March 31,
20212020
Cash paid for interest$337 $340 
Non-cash investing and financing activities
Accrued issuance costs$— $207 
Inventory transferred to property and equipment$2,813 $— 
Change in accounts payable and accrued liabilities related to purchases of property and equipment$751 $(34)
Release of repurchase rights on early exercised options$— $88 
(13)Commitments and Contingencies
Legal Proceedings
From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. The Company does not recognize gain contingencies until they are realized. Legal costs incurred relating to loss contingencies are expensed as incurred.
In July 2020, AbCellera Biologics Inc. (“AbCellera”) filed a complaint in the United States District Court for the District of Delaware, alleging that the Company infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by AbCellera by making, using, offering for sale, selling and/or importing the Company’s Beacon and Culture Station instruments and the OptoSelect chips, and sale of the Opto Plasma B Discovery Workflow: U.S. Patent Nos. 10,107,812, 10,274,494, 10,466,241, 10,578,618, 10,697,962, 10,087,408, 10,421,936 and 10,704,018 (“AbCellera I”).

In August 2020, AbCellera filed a second complaint in the United States District Court for the District of Delaware, making the same allegations with regard to U.S. Patent Nos. 10,718,768, 10,738,270, 10,746,737, and
18
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
10,753,933 (“AbCellera II”). In September 2020, AbCellera filed amended complaints in each of AbCellera I and AbCellera II adding The University of British Columbia as a named plaintiff. Also in September 2020, AbCellera and The University of British Columbia filed a third complaint in the United States District Court for the District of Delaware, making the same allegations with regard to U.S. Patent Nos. 10,775,376, 10,775,377, and 10,775,378 (“AbCellera III”). AbCellera and The University of British Columbia are seeking, among other things, judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees and treble damages for willful infringement). In addition to procedural motions, the Company has filed an answer and counterclaims in response to each of the AbCellera I, AbCellera II and AbCellera III lawsuits. The Company’s counterclaims in each lawsuit include counts for declaratory judgment of non-infringement of the asserted patents, for declaratory judgment of invalidity of the asserted patents and for declaratory judgment of unenforceability of the asserted patents due to inequitable conduct. The Company filed a motion to transfer the AbCellera I, AbCellera II and AbCellera III lawsuits to the United States District Court for the Northern District of California, which was granted and where the lawsuits have been consolidated and are now pending. On May 6, 2021, and pursuant to Court Order, AbCellera and The University of British Columbia reduced, without prejudice, the asserted patents in the case to the following: US Patent Nos. 10,087,408, 10,421,936, 10,738,270, 10,697,962, 10,753,933, 10,775,376 and 10,775,378.

In August 2020, the Company filed a complaint in the United States District Court for the Northern District of California against AbCellera and Lineage BioSciences, Inc., an entity previously acquired by AbCellera. The complaint includes two counts of unfair competition and one count of a declaratory judgment of non-infringement of U.S. Patent No. 10,058,839. The Company is seeking, among other things, damages and a judgment of non-infringement. In October 2020, the Company filed an amended complaint asserting the same three counts and AbCellera and Lineage filed a motion to dismiss the amended complaint, which was granted, without prejudice, in part. The unfair competition claims remain pending.

The Company believes that the patent assertions by AbCellera and The University of British Columbia are without merit and intends to defend itself vigorously. The Company also intends to proceed with its claims and counterclaims against AbCellera and The University of British Columbia. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in these lawsuits could subject the Company to significant liabilities, require it to seek licenses from or pay royalties to AbCellera and/or The University of British Columbia, or prevent it from manufacturing, selling or using certain of its products, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects.
No provision has been made for litigation because the Company believes that it is not probable that a liability had been incurred as of March 31, 2021.
The Company is not currently involved in any other claims or legal actions, nor is management aware of any potential claims or legal actions, for which the ultimate disposition could have a material adverse effect on the Company’s financial position, results of operations, or liquidity.
Product Warranty
The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands):
19
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Three months ended March 31,
20212020
Balance, beginning of period$1,271 $1,065 
Adjustments to existing warranties(218)(122)
Provision for new warranties375 330 
Settlement of pre-existing warranties(160)(80)
Balance, end of period$1,268 $1,193 
(14)Net Loss Attributable to Common Stockholders Per Share
Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards. Awards granted with performance conditions are excluded from the shares used to compute diluted earnings per share until the performance conditions associated with the awards are met.
The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data):
Three months ended March 31,
20212020
Numerator
Net loss attributable to common stockholders$(15,435)$(8,425)
Cumulative undeclared dividends on Series D convertible preferred stock— (797)
Net loss attributable to common stockholders, basic and diluted$(15,435)$(9,222)
Denominator
Weighted-average shares used to compute net income per share, basic and diluted65,259,3983,047,967
Net loss per share
Net loss per share attributable to common stockholders, basic and diluted$(0.24)$(3.02)
Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect:
Three months ended March 31,
20212020
Convertible preferred stock (on an if-converted basis)— 50,462,272 
Options to purchase common stock8,399,147 10,456,747 
Restricted stock units356,725 — 
Restricted shares of common stock related to early exercise of options— 27,032 
Warrants to purchase Series C convertible preferred stock— 136,519 
Total8,755,872 61,082,570 
(15)Segments
20
Berkeley Lights, Inc.
Notes to Condensed Consolidated Financial Statements
(Unaudited)
Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has a single reportable segment structure. The Company’s principal operations and decision-making functions are located in the United States.
The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands):
Three months ended March 31,
20212020
North America$7,362 $8,481 
Asia Pacific8,431 4,860 
Europe2,835 437 
$18,628 $13,778 
North America includes the United States and related territories. Asia Pacific also includes Australia.
As of March 31, 2021 and December 31, 2020, substantially all of the Company’s long-lived assets were located in the United States of America.
21

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements about:

•estimates of our addressable market, market growth, future revenue, key performance indicators, expenses, capital requirements and our needs for additional financing;
•the implementation of our business model and strategic plans for our products, workflows and technologies;
•our ability to successfully implement alternative non-direct purchase channels, including subscription and partnership offerings and the design of any such alternatives;
•our expectations regarding the rate and degree of market acceptance of our platform;
•competitive companies and technologies and our industry;
•our ability to manage and grow our business by expanding our sales to existing customers or introducing our products and workflows to new customers;
•our ability to develop and commercialize new products and workflows;
•our ability to establish and maintain intellectual property protection for our products and workflows or avoid or defend claims of infringement, including with respect to our intellectual property litigation with AbCellera and The University of British Columbia;
•the performance of third party manufacturers and suppliers;
•the potential effects of government regulation;
•our ability to hire and retain key personnel and to manage our future growth effectively;
•our ability to obtain additional financing in future offerings;
•the volatility of the trading price of our common stock;
•our ability to attract and retain key scientific and engineering personnel;
•our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;
•our expectations regarding the use of proceeds from our initial public offering in July 2020; and
•our expectations about market trends.

Forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

22

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the fiscal year ended December 31, 2020 included in Annual Report on Form 10-K and filed with the Securities and Exchange Commission on March 12, 2021. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2020, elsewhere in this Quarterly Report on Form 10-Q, and our other reports filed with the SEC.
Overview
Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. This is a new way to capture and interpret the qualitative language of biology and translate it into single-cell specific digital information, referred to as Digital Cell Biology. We currently focus on enabling the large and rapidly growing markets of antibody therapeutics, cell therapy and synthetic biology with our platform.
The Berkeley Lights Platform can be used to characterize the performance of cells relevant to the desired cell-based product early in the discovery process and then connect this phenotypic data to the genetic code for each cell. In contrast, current genomic technologies find sequences first and fail to deliver the functional information early in the process. Performing functional validation early means letting poorly performing cells fail early while rapidly advancing the best candidates forward, before incurring significant research and development expense. Our platform repeats this process of fail and advance many times throughout the process, delivering the best cells for what we believe will deliver the best product.
Our platform is a fully integrated, end-to-end solution, comprised of proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems and advanced application and workflow software. Customers load onto our system their live cell samples, as well as media and reagents, then the cells are imported onto our OptoSelect chips where integrated workflows are performed to assess specific cell functions and attributes. Our platform captures and delivers rich single-cell data to find the best cells. Our platform leverages proprietary OptoElectro Positioning (“OEP”) technology, which enables deterministic positioning of living single cells and other micro-objects using light. OEP is a core technology of our platform and allows for a high level of control over live single cells or other micro-objects throughout the functional characterization process.
Our commercial workflows, each of which are distinct offerings, are made up of four modules we call Import, Culture, Assay and Export. These modules can be adapted, interchanged and deployed with a variety of single-cell assays to address specific applications and a variety of cell types. We believe this versatility facilitates rapid development of new workflow offerings and expansive workflow commercialization opportunities. We have developed and will continue to develop and commercialize proprietary workflows across large markets by leveraging existing workflows and assays. Over time, our goal is to enable customers to standardize many of their processes on our platform utilizing our workflows. We believe we are the only company commercializing a
23

platform that can do this in a scalable way. From the initial launch of our platform in 2016 through March 31, 2021, we have commercially launched nine workflows.
Our customer base is comprised of companies from the pharmaceutical industry, biotechnology companies, government and academia institutions who leverage our platforms and workflows across established industry markets, including antibody therapeutics, cell therapy, gene therapy and synthetic biology. In the quarter ended March 31, 2021 we entered the gene therapy market upon execution of a development agreement with a new customer related to viral vector workflow development.
Historically, we have financed our operations primarily from the issuance and sale of convertible preferred stock, borrowings under our long-term debt agreement, as well as cash flows from operations. On July 21, 2020, we closed our initial public offering (the “IPO”), in which we sold 9,315,000 shares of common stock (which included 1,215,000 shares that were sold pursuant to the full exercise of the IPO underwriters’ option to purchase additional shares) at a price to the public of $22.00 per share. We received aggregate net proceeds of $187.9 million after deducting, offering costs, underwriting discounts and commissions of $17.0 million.
Since our inception in 2011, we have incurred net losses in each year. Our net losses were $15.4 million and $8.4 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, we had an accumulated deficit of $207.3 million and cash and cash equivalents totaling $230.2 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future.
Certain of our financial results and other key operational developments for the three months ended March 31, 2021 include the following:
•Total revenue for the three months ended March 31, 2021 was $18.6 million compared to $13.8 million for the same period in 2020. The increase was primarily due to increased product revenue from platform and systems sales, including fixed-term sales-type lease arrangements and subscription arrangements, resulting from our continued growth in customer base in the Antibody Therapeutics market, as well sales of our consumables driven by our increased installation base. We also saw an increase in service revenue from joint development and partnership agreements driven by the execution of an agreement in the first quarter of 2021 with a new customer related to viral vector workflow development. While our customers continue to be impacted by the COVID-19 pandemic, the impact is more directly related to our ability to install and train with customers in certain geographies and locations, whereas delays in purchasing decisions and negotiations for COVID-19 based reasons are becoming less frequent.
•Gross profit in absolute dollars for the three months ended March 31, 2021 increased compared to the same period in 2020, however gross margin declined. This was the result of the mix of products sold and services provided in the quarter, including service revenue associated with joint development and partnership agreements under which we provide services on a time-and-materials basis, as well as the regional mix of platform sales. Gross margin on the joint development and partnership agreements was also impacted by the buy-down in prior periods of two of the workflow programs that are being developed in collaboration with Ginkgo Bioworks which, while not impacting our costs incurred, does serve to reduce revenue and gross margin related to these specific programs upon execution and on a go-forward basis. Gross profit and margins were also impacted by the timing of services delivered to customers under extended warranty agreements, which can vary from period to period depending on when such services are requested by our customers.
•Operating expenses for the three months ended March 31, 2021 increased compared to the same period in 2020 due to the overall growth in our business, including the overall expansion of our operations and costs associated with being a public company and litigation expenses. We continue to invest in ongoing research and development activities related to testing and qualification materials and other costs related to various projects to develop and improve systems, workflows and assays.
24

COVID-19 Update

In response to the COVID-19 pandemic and various resulting government directives, we took proactive measures to protect the health and safety of our employees, contractors, customers and visiting vendors and suppliers. We continue to monitor the implications of the COVID-19 pandemic on our business, as well as our customers’ and suppliers’ businesses. Some of the measures we have taken were as follows:
•During this pandemic, we moved quickly to place platforms and to provide reagents to researchers around the world working to understand COVID-19 and identify antibodies to support the development of therapies and cures for the disease with the aim to accelerate the discovery of neutralizing antibodies. Our platforms, assays and workflows are a useful tool for infectious disease research because they are able to be leveraged for antibody discovery using the blood of recovering patients as the foundation for therapeutics.
•Berkeley Lights has been designated an essential business that can continue operations during the COVID-19 pandemic. In early March 2020, we promptly instituted protocols to have many personnel work remotely. At the same time, because of our continued designation as an essential business, many employees continue to come on-site to our facility in Emeryville, California to undertake research and development activities that support essential operations to, among other things, provide critical products to researchers and support the important research and development being undertaken by our customers. For those employees coming on-site, we have implemented social distancing and other protective measures in order to protect their health and safety, including a COVID-19 Prevention Program. We have also restricted business travel and have limited access to our campus and other facilities to outside visitors other than vendors, suppliers and partners who are integral to supporting our business. To date, these arrangements have not materially affected our ability to maintain our business operations, including the operation of financial reporting systems, internal control over financial reporting and disclosure controls and procedures.
•Our production, shipping and customer service functions remain operational to maintain a continuous supply of products both to our customers and for our internal research and development activities. We are communicating regularly with our suppliers so that our supply chain remains intact and we have not yet experienced any material supply issues. Our customer service teams around the world are operating remotely and remain available to assist our customers and partners as needed and, for certain customers, our service and support team members have been required to complete country-specific quarantine requirements, which adds both time and costs to our business operations and customer responsiveness.
•Initially, as a result of travel restrictions and shelter-in-place orders, we experienced an impact on our ability to ship and install systems, as well train customers in certain geographies. In July 2020, we began developing, and continue to develop, remote learning capabilities to help our customers and partners operate their Berkeley Lights platforms and reduce the number of customer/partner on-site visits our field application scientists and field support engineers need to make in view of certain travel restrictions and country-specific quarantine requirements.
•We are actively reviewing and managing costs to navigate the current environment. However, to date, the COVID-19 pandemic has not had a material adverse effect on our expenses.
While we have developed and implemented, and continue to develop and implement, health and safety protocols and business continuity plans in an effort to mitigate the negative impact of COVID-19 to our employees and business, the extent of the impact of the pandemic on our business and financial results will continue to depend on numerous evolving factors that we are not able to accurately predict, including the duration of the pandemic, the emergence of new variants of the virus, the likelihood of a resurgence of positive cases, the development and availability of effective treatments and vaccines and the global economic conditions during and after the
25

pandemic. We expect these disruptions to impact our future operating results. However, the related financial impact and duration of these disruptions cannot be reasonably estimated at this time.
Components of results of operations
Revenue
Our revenue consists of both product and service revenue, which is generated through the following revenue streams: (i) direct platform sales (advanced automation systems, fully-paid workflow license agreements and platform support), (ii) recurring revenue (annual workflow license agreements, workflow subscription agreements, consumables, service and extended or enhanced warranty contracts), and (iii) revenue from partnerships related to our joint development agreements, and to a lesser extent feasibility studies. Sales of advanced automation systems, recurring revenue from consumables, workflow subscription agreements, and workflow licenses are defined as product revenue; and revenue from joint development agreements and partnerships, service and extended or enhanced warranty contracts, feasibility studies and platform support are defined as service revenue in our consolidated results of operations.
Direct platform sales: Direct platform sales are comprised of our customers, distributors and dealers directly purchasing our advanced automation systems, which include the Beacon and Lightning systems and Culture Station instrument. Direct platform sales can also include fixed-term sales-type lease arrangements with certain qualified customers. These direct purchases included, during our early customer engagements, a fully-paid workflow license to practice the desired workflow(s) in a specific field of use. In addition, we also offer platform support to the extent customers require further system and workflow optimization following platform implementation. Direct platform sales were as follows for the periods presented:
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
Direct platform sales $11,116$9,448$1,66818 %
Total revenue$18,628$13,778$4,85035 %
Direct platform sales as % of total revenue 60 %69 %

Recurring revenue: Each platform placement, depending on the chosen access model, drives various streams of recurring revenue. With each workflow, our customers require certain consumables such as our OptoSelect chips and reagent kits to run their workflows. The OptoSelect chips can only be used with our platform and we believe there are no alternative after-market options that can be used as a substitute. Each OptoSelect chip is considered, and labeled for, single-use and only used for one workflow. Consumables are sold without the right of return and revenue is recognized upon transfer of control. We also offer our customers extended warranty and service programs for regular system maintenance and system optimization. These services are provided primarily on a fixed fee basis. We recognize revenue from the sale of an extended warranty contract over the respective coverage period. Extended and enhanced warranty, as well as service contracts, are typically short-term in nature, generally covering a one-year period.

Recurring revenue may also include annually renewable workflow licenses as well as quarterly workflow subscription revenue from annual or multi-year subscription agreements. In late 2019, we piloted a subscription option for the antibody discovery and cell line development workflows that was formally launched in February 2020. We are still in the early commercialization phase of assessing market acceptance of the subscription access model and it is possible the model may change as we engage with and learn from initial subscription customers.


26

Recurring revenue was as follows for the periods presented:
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
Recurring revenue $4,394$2,479$1,91577 %
Total revenue$18,628$13,778$4,85035 %
Recurring revenue as % of total revenue 24 %18 %

Revenue from joint development agreements and partnerships: Joint development agreements and partnerships, including collaboration agreements, are arrangements whereby we provide services for the development of new workflows, cell, or organism types, or deliver specific biological assets to meet specific customers’ needs. Such contracts can be executed on a time-and-materials basis or include defined milestones associated with these development activities over extended periods of time, some in excess of twenty-four months. Our joint development agreements that include formal milestones may include formal customer acceptance clauses as each milestone is completed as well as an approval to proceed with the next milestone. Some development agreements may also include a prerequisite feasibility study to determine proof of concept before any work is initiated. We recognize revenue over time using an input measure of progress based on costs incurred to date as compared to the total estimated costs (i.e. percentage of completion), or in certain instances on a time-and-materials basis, depending on the terms of the development agreement. We periodically review and update our estimates which may adjust revenue recognized for the period. Revenue from joint development and partnership agreements can vary over time as different projects start and complete. On occasion, we also perform feasibility studies prior to a direct platform sale in the event customers require specific platform validation prior to purchase.

Joint development agreement and partnership related revenue was as follows for the periods presented:
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
Joint development agreement and partnership revenue$3,118$1,851$1,26768 %
Total revenue$18,628$13,778$4,85035 %
Joint development agreement and partnership revenue as % of total revenue 17 %13 %
Costs of sales, gross profit and gross margin
Product cost of sales. Cost of sales associated with our products primarily consists of manufacturing related costs incurred in the production process, including personnel and related costs, costs of component materials, labor and overhead, packaging and delivery costs and allocated costs, including facilities and information technology. These costs also include the costs associated with the standard assurance-type product warranty provided on our platforms, which are recorded at the time of sale.
Service cost of sales. Cost of sales associated with our services primarily consists of personnel and related costs, expenses related to the development of customized platforms and workflows, feasibility studies on our platforms and service and warranty costs to support our customers. We maintain continuous efforts to increase reliability and uptime of our advanced automation systems.

Gross profit and gross margin. Gross profit is calculated as revenue less cost of sales. Gross margin is gross profit expressed as a percentage of revenue. Our gross profit in future periods will depend on a variety of factors,
27

including: market conditions that may impact our pricing; sales mix among platform access options, including the regional mix of sales; sales mix changes among consumables, advanced automation systems and services; product mix changes between established products and new products; excess and obsolete inventories; our cost structure for manufacturing operations relative to volume; and product warranty obligations. We expect cost of sales to increase in absolute dollars in future periods as our revenue grows, and as we plan to hire additional employees to support our manufacturing, operations, service and support organizations.
Operating expenses
Research and development. Research and development costs primarily consist of salaries, benefits, incentive compensation, stock-based compensation, laboratory supplies, materials expenses and allocated facilities and IT costs for employees and contractors engaged in research and product development. We expense all research and development costs in the period in which they are incurred.
We plan to continue to invest in our research and development efforts, including hiring additional employees, to enhance existing products and develop new products. As a result, we expect that our research and development expenses will continue to increase in absolute dollars in future periods. We expect these expenses to vary from period to period as a percentage of revenue.

General and administrative. Our general and administrative expenses primarily consist of salaries, benefits and stock-based compensation costs for employees in our executive, accounting and finance, legal and human resource functions, as well as professional services fees, such as consulting, audit, tax and legal fees, general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to increase in absolute dollars, primarily due to increased headcount to support anticipated growth in the business and due to incremental costs associated with operating as a public company. We expect these expenses to vary from period to period as a percentage of revenue.

Sales and marketing. Our sales and marketing expenses consist primarily of salaries, benefits, sales commissions and stock-based compensation costs for employees within our commercial sales functions, as well as marketing, travel expenses and allocated facilities and IT costs. We expect our sales and marketing expenses to increase in absolute dollars as we expand our commercial sales, marketing and business development teams, increase our presence globally and increase marketing activities to drive awareness and adoption of our platform. While these expenses may vary from period to period as a percentage of revenue, we expect these expenses to increase as a percent of sales in the short-term as we continue to grow our commercial organization to support anticipated growth in the business.
We expect our aggregate stock-based compensation to continue to increase in absolute dollar terms.
Other income (expense)
Interest expense. Interest expense consists primarily of interest related to borrowings under our debt obligations.
Interest income. Interest income primarily consists of interest earned on our cash and cash equivalents which are invested in cash deposits and in money market funds.
Other income (expense), net. Other income (expense), net consists primarily of foreign currency exchange gains and losses. Foreign currency exchange gains and losses relate to transactions and asset and liability balances denominated in currencies other than the U.S. dollar, primarily related to our operations in the United Kingdom. We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates.

28

Provision for income taxes
Our provision for income taxes consists primarily of foreign taxes and state minimum taxes in the United States. As we expand the scale and scope of our international business activities, any changes in the United States and foreign taxation of such activities may increase our overall provision for income taxes in the future.
Results of operations
The following tables set forth our results of operations for the periods presented:
Three months ended March 31,
(in thousands)20212020
Revenue:
Product revenue$13,533 $10,683 
Service revenue5,095 3,095 
Total revenue18,628 13,778 
Cost of sales:
Product cost of sales3,703 2,620 
Service cost of sales2,474 1,179 
Total cost of sales (1)
6,177 3,799 
Gross profit12,451 9,979 
Operating expenses:
Research and development (1)
13,027 10,976 
General and administrative (1)
8,967 3,997 
Sales and marketing (1)
5,606 3,234 
Total operating expenses27,600 18,207 
Loss from operations(15,149)(8,228)
Other income (expense):
Interest expense(354)(357)
Interest income66 151 
Other income (expense), net19 25 
Loss before income taxes(15,418)(8,409)
Provision for income taxes17 16 
Net loss and net comprehensive loss$(15,435)$(8,425)
(1)Amounts include stock-based compensation as follows:
Three months ended March 31,
(in thousands)20212020
Cost of sales$42 $6 
Research and development1,061 511 
General and administrative1,372 529 
Sales and marketing2,019 133 
Total stock-based compensation expense$4,494 $1,179 
29

Comparison of the three months ended March 31, 2021 and 2020
Revenue
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
Product revenue$13,533 $10,683 $2,850 27 %
Service revenue5,095 3,095 2,000 65 %
Total revenue$18,628 $13,778 $4,850 35 %
Product revenue increased by $2.9 million, or 27%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. The increase was primarily driven by strong demand from the Antibody Therapeutics market, resulting in an increase of $1.4 million from platform and system sales, including sales-type lease arrangements and license arrangements related to our workflows, an increase of $1.1 million in consumables sales driven by additional demand from our customers due to the increase in our installed base, and an increase of $0.4 million in subscription arrangement and related revenue driven by the launch of our subscription access program in 2020. During the three months ended March 31, 2021, we sold eight platforms, including placements associated with subscription arrangements, as compared to the three months ended March 31, 2020 in which we sold six platforms.
Service revenue increased by $2.0 million, or 65%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. The increase was primarily driven by higher revenue associated with joint development agreement and partnership revenue of $1.4 million primarily due to the execution of an agreement in the first quarter of 2021 with a new customer related to viral vector workflow development as well as an increase from sales in service warranty and application support arrangements of $0.8 million, which resulted from the timing of activities performed and the timing of warranty renewals by our customers as their standard warranty periods expire and our platform placements increase. The increase in service revenue was partially offset by a decrease in revenue from feasibility studies resulting from the timing of such arrangements.
Cost of sales, gross profit and gross margin
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
Product cost of sales$3,703 $2,620 $1,083 41 %
Service cost of sales2,474 1,179 1,295 110 %
Total cost of sales$6,177 $3,799 $2,378 63 %
Gross profit$12,451 $9,979 $2,472 25 %
Gross margin67 %72 %
Product cost of sales increased by $1.1 million, or 41% for the three months ended March 31, 2021, respectively, compared to the three months ended March 31, 2020 and was in line with product revenue growth.
Service cost of sales increased by $1.3 million, or 110% for the three months ended March 31, 2021, respectively, compared to the three months ended March 31, 2020. The increase was primarily due to costs incurred for joint development agreements under which we provide services on a time-and-materials basis, as well as increased costs for extended warranty services as a result of the nature and timing of work performed under such arrangements.
30

Gross profit increased by $2.5 million, or 25%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. Gross margin declined by 5% for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The decline in gross margin was driven by the mix of products sold and services provided in the quarter, including service revenue associated with joint development and partnership agreements under which we provide services on a time-and-materials basis. Gross margin on the joint development and partnership agreements was also impacted by the buy-down in prior periods of two of the workflow programs that are being developed in collaboration with Ginkgo Bioworks which, while not impacting our costs incurred, does serve to reduce revenue and gross margin related to these specific programs upon execution and on a go-forward basis. While not as significant, gross margin was also impacted by the timing of services delivered to customers under extended warranty agreements, which can vary from period to period depending on when such services are requested by our customers.
Operating Expenses
Research and development
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
Research and development$13,027 $10,976 $2,051 19 %
Research and development expense increased by $2.1 million, or 19%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. The increase was due to a $0.7 million increase in personnel-related expenses, including a $0.5 million increase in stock-based compensation expense primarily due to increased headcount as a result of our continued growth as well as a $1.4 million increase in other costs, including testing and qualification materials and other costs related to various projects to develop and improve systems, workflows, consumables and assays.

General and administrative
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
General and administrative $8,967 $3,997 $4,970 124 %

General and administrative expense increased by $5.0 million, or 124%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. The increase was due to a $1.9 million increase in personnel-related expenses, including a $0.8 million increase in stock-based compensation expense primarily due to the growth of our operations, a $2.0 million increase in outside legal fees, including patent litigation, and a $1.0 million increase of insurance costs related primarily to requirements associated with operating as a public company.
31

Sales and marketing
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
Sales and marketing$5,606 $3,234 $2,372 73 %

Sales and marketing expense increased by $2.4 million, or 73%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. The increase was due to a $2.5 million increase in personnel-related expenses, including a $1.9 million increase in stock-based compensation expense as a result of increased headcount and certain performance awards granted to a non-employee strategic advisor, partially offset by a decrease of $0.1 million in marketing, advertising, travel and other costs as business travel, trade shows and other events were impacted by restrictions imposed due to the COVID-19 pandemic during the three months ended March 31, 2021.
Interest expense
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
Interest expense$354 $357 $(3)(1 %)
Interest expense remained flat at $0.4 million for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. Interest expense resulted primarily from interest incurred on our loan from East West Bank, which carries interest at a fixed rate of interest.
Interest income
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
Interest income $66 $151 $(85)(56 %)
Interest income decreased by $0.1 million, or 56%, for the three months ended March 31, 2021, compared to the three months ended March 31, 2020. The decrease was primarily due to lower interest received on our cash and short-term deposits due to a decline in interest rates.
Other income (expense), net
Three months ended March 31,Three month change
(in thousands, except percentages)20212020Amount%
Other income (expense), net $19 $25 $(6)24 %
32

Other income for the three months ended March 31, 2021 and 2020 was mainly comprised of foreign exchange gains and losses and other miscellaneous income.
Liquidity and capital resources
As of March 31, 2021, we had approximately $230.2 million in cash and cash equivalents which were primarily held in U.S. short-term bank deposit accounts and money market funds. Restricted cash of $0.3 million serves as collateral for our corporate credit card program. We have generated negative cumulative cash flows from operations since inception through March 31, 2021.
We expect to incur additional operating losses in the foreseeable future as we continue to invest in the research and development of our product offerings, commercialize and launch platforms, and expand into new markets. Our future capital requirements will depend on many factors including our revenue growth rate, research and development efforts, the impacts of the COVID-19 pandemic, the timing and extent of additional capital expenditures to invest in existing and new facilities as well as our manufacturing operations, the expansion of sales and marketing and the introduction of new products. We have and may in the future enter into arrangements to acquire or invest in businesses, services and technologies, and any such acquisitions or investments could significantly increase our capital needs.
We currently anticipate making aggregate capital expenditures between approximately $7.0 million and $8.0 million during the next 12 months, which is expected to primarily include equipment to be used for manufacturing and research and development, as well as spend associated with the expansion of our facilities to support the growth of our operations.
Based on our current business plan, we believe our existing cash and cash equivalents and anticipated cash flows from operations will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months.
Sources of liquidity
Since our inception, we have financed our operations primarily from the issuance and sale of equity securities, borrowings under long-term debt agreements, and to a lesser extent, cash flow from operations. In July 2020, we completed our IPO, resulting in the receipt of aggregate proceeds of $187.9 million, net of offering costs, underwriter discounts and commissions of $17.0 million.
East West Bank Loan and Security Agreement
In May of 2018, we entered into a Loan and Security Agreement, or the EWB Loan Agreement, with East West Bank, or EWB, which was subsequently amended in April of 2019 and March of 2020, providing us with the ability to borrow up to $20.0 million. The full amount of the loan was funded in May of 2018, and $20.0 million of term loan borrowings were outstanding as of March 31, 2021. Borrowings under the term loan mature on May 23, 2022 and accrue interest at a fixed rate of 6.73% per annum. We are required to make interest only payments on the term loan through May of 2021, after which equal monthly installments of principal and interest are due.
The EWB Loan Agreement is collateralized by substantially all of our property, except for intellectual property, which is subject to a negative pledge. The EWB Loan Agreement contains customary negative covenants that limit our ability to, among other things, incur additional indebtedness, grant liens, make investments, repurchase stock, pay dividends, transfer assets and merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity. The EWB Loan Agreement also contains customary affirmative covenants, including requirements to, among other things, deliver audited financial statements. In addition, the EWB Loan Agreement contains financial covenants that require us to maintain a certain percentage of our total cash holdings in accounts with EWB as well as maintain certain ratios of cash to cash burn. If we default under the EWB Loan Agreement and if the default is not cured or waived, the lender
33

could cause any amounts outstanding to be payable immediately. Under certain circumstances, the lender could also exercise its rights with respect to the collateral securing such loans. Moreover, any such default would limit our ability to obtain additional financing, which may have an adverse effect on our cash flow and liquidity.
We were in compliance with all covenants under the EWB Loan Agreement as of March 31, 2021.
Cash flows
The following table summarizes our cash flows for the periods presented:
Three months ended March 31,
(in thousands)20212020
Net cash (used in) provided by:
Operating activities$(11,360)$(9,988)
Investing activities(402)(760)
Financing activities8,519 21 
Net decrease in cash and cash equivalents and restricted cash$(3,243)$(10,727)


Operating activities

Net cash used in operating activities of $11.4 million for the three months ended March 31, 2021 was attributable to a net loss of $15.4 million and cash outflows of $2.3 million from changes in our net operating assets and liabilities, partially offset by non-cash charges of $6.4 million, primarily related to stock-based compensation and depreciation and amortization. Cash outflow from our net operating assets and liabilities was primarily due to a $2.7 million increase in inventories resulting from an increase in raw materials and finished goods to support revenue growth and anticipated demand, a $3.5 million increase in accounts receivable due to an increase in revenue and the timing of invoicing and a $1.0 million increase in prepaid and other current assets resulting from the overall growth in our business and operations, partially offset by a $5.7 million increase in deferred revenue and accounts payable due to the timing of advanced billings and revenue recognition as well as the timing of vendor invoicing and related payments.

Net cash used in operating activities of $10.0 million for the three months ended March 31, 2020 was attributable to a net loss of $8.4 million and cash outflows of $4.6 million from changes in our net operating assets and liabilities, partially offset by non-cash charges of $3.0 million, primarily related to stock-based compensation and depreciation and amortization. Cash outflow from our net operating assets and liabilities was primarily due to a $3.5 million increase in inventories due an increase in raw materials and finished goods to support revenue growth and anticipated demand and a $2.0 million decrease in deferred revenue due to the timing of revenue recognition on previously deferred revenue, partially offset by a $1.5 million increase in accounts payable and accrued expenses due to the timing of vendor payments.

Investing activities

Net cash used in investing activities was $0.4 million in the three months ended March 31, 2021 compared to $0.8 million in the three months ended March 31, 2020. The decrease was primarily driven by the timing of capital expenditures. Capital expenditures for the first quarter of 2021 include the expansion of our biofoundry operations to support current and planned programs.
34

Financing activities
Net cash provided by financing activities was $8.5 million for the three months ended March 31, 2021 compared to $21,000 for the three months ended March 31, 2020. Net cash provided by financing activities during the three months ended March 31, 2021 related to proceeds received from the issuance of common stock upon the exercise of stock options as well as proceeds received related to the issuance of common stock under our employee stock purchase plan. Net cash provided by financing activities for the three months ended March 31, 2020 related to proceeds received from the issuance of common stock upon the exercise of stock options.
Concentration of credit risk
Most of the Company’s customers are located in the United States and Asia Pacific. For the three months ended March 31, 2021, two customers accounted for 11% and 10% of revenue. For the three months ended March 31, 2020, six customers accounted for 17%, 14%, 13%, 13%, 12% and 12% of revenue.
As of March 31, 2021, five customers comprised 25%, 22%, 12%, 11% and 11% of accounts receivable.
Contractual obligations and commitments
There have been no material changes to our contractual obligations as of March 31, 2021, as compared to those disclosed in the Annual Report on Form 10-K for the year ended December 31, 2020, with the following exceptions.
We purchase raw materials for inventory, services and equipment from a variety of vendors, including our contract manufacturers that manufacture our instruments and certain providers of our components for our consumable manufacturing. Total purchase obligations that are enforceable and legally binding on us and that specify all significant terms were $46.4 million as of March 31, 2021, of which $15.8 million are expected to be become due after December 31, 2021 and beyond.
Off-balance sheet arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet financing arrangements or any relationships with unconsolidated entities or financial partnerships, including entities sometimes referred to as structured finance or special purpose entities, that were established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.
Critical accounting policies and estimates
We have prepared our condensed consolidated financial statements in accordance with United States generally accepted accounting principles (“U.S. GAAP”). Our preparation of these condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.
There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled “Management’s Discussion and Analysis of Financial Condition and Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 12, 2021, with the following exceptions.
35

We maintain an incentive compensation plan under which incentive stock options, nonqualified stock options and restricted stock units (“RSUs”) are granted primarily to employees and non-employee consultants. Stock-based compensation expense for stock-based awards is based on the grant date fair value of the awards. We determine the fair value of RSUs based on the closing value of our stock price listed on Nasdaq at the date of the grant.
We estimate the fair value of stock option awards on the grant date using the Black-Scholes option-pricing model. The fair value of stock option awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock option awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period, provided the grantee remains an employee or consultant of the Company through each applicable vesting date. We record a cumulative adjustment to compensation expense for performance-based awards if there is a change in determination of whether it is probable that the performance condition will be achieved. If the performance goals are not achieved, no compensation expense is recognized and any previously recognized compensation expense is reversed. We record forfeitures as they occur.
Recent Accounting Pronouncements
See Note 2, “Summary of Significant Accounting Policies” in our Notes to the Unaudited Condensed Consolidated Financial Statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q for a discussion of recent accounting pronouncements.
JOBS Act accounting election
We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected not to use this extended transition period. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002.
Item 3.    Quantitative and Qualitative Disclosures about Market Risk.
Interest rate risk
Customer financing exposure. We are indirectly exposed to interest rate risk because many of our customers depend on debt financings to purchase our platforms and systems. An increase in interest rates could make it challenging for our customers to obtain the capital necessary to make such purchases on favorable terms, or at all. Such factors could reduce demand or lower the price we can charge for our platforms and systems, thereby reducing our net sales and gross profit.
Bank deposit and money market exposure. As of March 31, 2021, we had cash and cash equivalents, including restricted cash, of $230.4 million, which consisted primarily of money market funds and bank deposits. The primary objective of our investment is to preserve principal and provide liquidity. These money market funds, and bank deposits generate interest income at variable rates below 1%. A hypothetical 100 basis point decrease in interest rates would have lowered our interest income for the three months ended March 31, 2021 by $0.1 million and increased our net loss by this amount.
Foreign currency risk
Through March 31, 2021, we did not generate any revenue denominated in foreign currencies. As we expand our presence in international markets, to the extent we are required to enter into agreements denominated in a
36

currency other than the US dollar, our results of operations and cash flows may increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.
Item 4.    Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Due to the COVID 19 pandemic, a significant portion of our employees are now working from home, and are also under shelter-in-place orders or other restrictions. Business continuity plans were activated in order to mitigate the impact to our control environment, operating procedures, data and internal controls. The design of our processes and controls allow for remote execution with accessibility to secure data.
We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our “disclosure controls and procedures” as defined in Exchange Act Rule 13a-15(e) and 15d-15(e). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of March 31, 2021 our disclosure controls and procedures were effective at a reasonable assurance level to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
We also carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of our “internal control over financial reporting” as defined in Exchange Act Rule 13a-15(f) and 15d-15(f) to determine whether any changes in our internal control over financial reporting occurred during the three months ended March 31, 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, there were no such changes in our internal control over financial reporting that occurred during the three months ended March 31, 2021 despite the fact that many of our associates are working remotely due to the COVID-19 pandemic. We continue to monitor and assess the COVID-19 situation on our internal controls to minimize potential impacts on their design and operating effectiveness.
Limitations on the Effectiveness of Controls
Control systems, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems’ objectives are being met. Further, the design of any system of controls must reflect the fact that there are resource constraints, and the benefits of all controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of error or mistake. Control systems can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
37

Part II. OTHER INFORMATION.
Item 1.    Legal Proceedings.
See Note 13, “Commitments and Contingencies” under the heading “Legal Proceedings” in the Notes to the Unaudited Condensed Consolidated Financial Statements included in Part 1, Item 1 of this Quarterly Report on Form 10-Q for legal proceedings and related matters.
Item 1A. Risk Factors.
Factors that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors set forth in our Annual Report on Form 10-K filed with the SEC on March 12, 2021. The risks described in our Form 10-K and this Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently consider significant may also have an adverse effect on the Company. If any of the risks actually occur, our business, results of operations, cash flows or financial condition could suffer.
There have been no material changes to the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 12, 2021.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.
Sale of Unregistered Securities
There were no unregistered sales of the Company's equity securities during the three months ended March 31, 2021.
Use of Proceeds from our IPO
On July 21, 2020, we closed our initial public offering, in which we issued and sold 9,315,000 shares of our common stock, including the full exercise of the underwriters’ over-allotment option, at a public offering price of $22.00 per share for aggregate offering proceeds of $204.9 million. All of the shares of common stock issued and sold in the offering were registered under the Securities Act of 1933, as amended (“Securities Act”) pursuant to a registration statement on Form S-1 (File No. 333-239487), which was declared effective by the SEC on July 16, 2020.
Cash used since the initial public offering is described elsewhere in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our periodic reports filed with the SEC. As of the date of this filing, there has been no material change in the planned use of proceeds from our initial public offering as described in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 12, 2021.
Item 3.    Defaults Upon Senior Securities.
Not applicable.
Item 4.    Mine Safety Disclosures.
Not applicable.
Item 5.    Other Information.
None.
Item 6. Exhibits.
38

The following exhibits are filed with this Quarterly Report on Form 10-Q:
Incorporated by Reference
Exhibit NumberExhibit TitleFormFile No.ExhibitFiling DateFiled Herewith
X
X
X
X
101.INSXBRL Instance Document.X
101.SCHXBRL Taxonomy Extension Schema Document.X
101.CALXBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.X
101.LABXBRL Taxonomy Extension Label Linkbase Document.X
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.X
104Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101X
*This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in such filings
39


Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf of the undersigned thereunto duly authorized.

Berkeley Lights, Inc.

Date: May 11, 2021By:  /s/ Kurt Wood
Kurt Wood
Chief Financial Officer
(Principal Financial Officer)
40